Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
Bioorg Med Chem. 2011 Jan 1;19(1):229-42. doi: 10.1016/j.bmc.2010.11.029. Epub 2010 Dec 4.
A series of O-phenyl methyl-, ethyl- and benzylalanyl phosphoramidate pronucleotides derived from cytostatic 6-aryl-7-deazapurine ribonucleosides were prepared by the cross-coupling reactions of the 2',3'-isopropylidene protected 6-chloro-7-deazapurine ribonucleoside phosphoramidates with (het)arylboronic acids or -stannanes followed by deprotection. Most of the prepared prodrugs exerted in vitro cytostatic effects against both solid tumor and lymphoid cancer cells within low micromolar range of concentrations. These activities were in general weaker or comparable to the activities of the parent nucleosides. Additional testing of selected prodrugs suggests that the lack of activity improvement over parent nucleosides is not due to the lack of permeability or inefficient catabolism of alanyl-ester by intracellular hydrolases. More likely, active efflux of prodrugs may play a role in their weak cytotoxic activity.
一系列源于细胞抑制剂 6-芳基-7-脱氮嘌呤核苷的 O-苯甲基、乙基和苄基丙氨酰基磷酰胺核苷前药通过 2',3'-异亚丙基保护的 6-氯-7-脱氮嘌呤核苷磷酰胺与(杂)芳基硼酸或-锡烷的交叉偶联反应制备,然后进行脱保护。大多数制备的前药在低微摩尔浓度范围内对实体瘤和淋巴癌细胞表现出体外细胞抑制作用。这些活性通常比母核昔的活性弱或相当。对选定的前药的进一步测试表明,与母核昔相比,活性没有改善并不是由于细胞内水解酶对丙氨酰酯缺乏通透性或无效代谢。更可能的是,前药的主动外排可能在其弱细胞毒性活性中起作用。